BioNTech has acquired Chinese cancer drugmaker Biotheus in a near $1bn deal, as the Covid-19 vaccine maker taps into the country’s health sciences expertise to develop promising immunotherapy drugs.
The deal gives the German biotech control of a drug class that has shown potential to outperform Merck’s blockbuster cancer treatment Keytruda, the best-selling drug globally in 2023 with $25bn in sales.